Jeffrey Tong

Jeffrey K.
Tong is currently Executive Chairman at Ambys Medicines, Inc. since 2021.
He is Chairman at Septerna, Inc. since 2021, Director at Asher Biotherapeutics, Inc., Director at Terremoto Biosciences, Inc., and Partner at Third Rock Ventures LLC since 2016.
Former roles include President & Chief Executive Officer at Nora Therapeutics, Inc. from 2010 to 2015, Chief Executive Officer at Marea Therapeutics, Inc., Chairman at Delinia, Inc. from 2016 to 2017, Independent Director at Nurix Therapeutics, Inc. from 2018 to 2022, Independent Director at Maze Therapeutics, Inc., Director at Regeneration NewCo, Inc., Non-Executive Director at Rapport Therapeutics, Inc. in 2024, Consultant at McKinsey & Co., Inc., and Vice President-Corporate & Product Development at Infinity Pharmaceuticals, Inc. Education includes undergraduate degree from Harvard College, graduate and doctorate degrees from Harvard University, and a graduate degree from Harvard Medical School.